Krebs Biochemicals & Industries Limited

KREBSBIO

INE268B01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:48 10/05/2024 BST			5-day change	1st Jan Change
65.89 ^INR	-4.55%		-9.22%	-15.89%

04-15	Krebs Biochemicals & Industries Limited Announces Resignation of Keyur Doshi as Company Secretary, Compliance Officer	CI
02-12	Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Krebs Biochemicals & Industries Limited Announces Resignation of Keyur Doshi as Company Secretary, Compliance Officer

April 15, 2024 at 08:42 am

Krebs Biochemicals & Industries Limited informed that Mr. Keyur Doshi, has resigned from the post of Company Secretary, Compliance officer and Key Managerial Personnel of the Company with effect from close of business hours of 1 April 2024 to pursue new career opportunities and he will be relieved from the services of the Company with effect from close of business hours on 15 April, 2024.

Latest news about Krebs Biochemicals & Industries Limited

Krebs Biochemicals & Industries Limited Announces Resignation of Keyur Doshi as Company Secretary, Compliance Officer	04-15	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer	01-17	CI
Andhra Pradesh Pollution Control Board Orders Production Halt at Krebs Biochemicals Plant	12-18	MT
Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer	20/10/23	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/08/23	CI
Krebs Biochemicals & Industries Limited Approves Resignation of Mr. Pabitrakumar Kalipada Bhattacharya as Managing Director	09/08/23	CI
Krebs Biochemicals Limited Announces Executive Changes, Effective 10 August 2023	09/08/23	CI
Krebs Biochemicals Trims Net Loss in Fiscal Q4	24/05/23	MT
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	24/05/23	CI
Krebs Biochemicals Names New CFO	03/02/23	MT
Krebs Biochemicals & Industries Limited Approves Appointment of Rohit Taparia as Company Secretary and Compliance Officer	03/02/23	CI
Krebs Biochemicals & Industries Limited Approves CFO Changes	03/02/23	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Krebs Biochemicals & Industries Limited Auditor Raises 'Going Concern' Doubt	05/09/22	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	01/08/22	CI
Taruni Banda Resigns as Company Secretary and Compliance Officer of Krebs Biochemicals & Industries Limited, Effective from August 6, 2022	01/08/22	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	23/05/22	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	12/02/22	CI
Krebs Biochemicals & Industries Limited announced that it has received INR 1 billion in funding from Ipca Laboratories Limited	29/12/21	CI
Krebs Biochemicals & Industries Limited Appoints Jitendra Shah as Additional Director, Non-Executive Category	09/11/21	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	09/11/21	CI
Krebs Biochemicals & Industries Limited to Consider Resignation of E J Babu as Non-Executive Director	02/11/21	CI
Krebs Biochemicals & Industries Limited announced that it expects to receive INR 1 billion in funding from Ipca Laboratories Limited	22/10/21	CI
Krebs Biochemicals & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	30/07/21	CI

Chart Krebs Biochemicals & Industries Limited

Duration

Period

Chart Krebs Biochemicals & Industries Limited

More charts

Company Profile

Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Companyâs pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.

Sector

Pharmaceuticals

Calendar

19/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KREBS BIOCHEMICALS & INDUSTRIES LIMITED	-15.89%	17.01M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.27B
OTSUKA HOLDINGS CO., LTD.	+24.52%	22.92B
SANDOZ GROUP AG	+20.29%	15.43B
CIPLA LIMITED	+7.48%	12.95B
ZYDUS LIFESCIENCES LIMITED	+42.51%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-8.84%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.13%	5.55B